Skip to main content

Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System

Abstract

Background

The first consensus Merkel cell carcinoma (MCC) staging system was published in 2010. New information on the clinical course prompts review of MCC staging.

Methods

A total of 9387 MCC cases from the National Cancer Data Base Participant User File with follow-up and staging data (1998–2012) were analyzed. Prognostic differences based on clinical and pathological staging were evaluated. Survival estimates were compared by disease extent.

Results

Sixty-five percent of cases presented with local disease, whereas 26 and 8 % presented with nodal and distant disease. Disease extent at presentation was predictive of 5-year overall survival (OS) with estimates of 51, 35, and 14 % for local, nodal, and distant disease. Tumor burden at the regional nodal basin was predictive of 5-year OS with estimates of 40 and 27 % for clinically occult and clinically detected nodal disease. For local disease, we confirm improved prognosis when the regional nodal basin was negative by pathological compared with clinical staging. We identified 336 cases with clinically detected nodal disease and unknown primary tumor and showed improved prognosis over cases presenting with concurrent primary tumor (OS estimates of 42 vs. 27 %).

Conclusions

Analysis of a national dataset of MCC cases validates the predictive value of disease extent at presentation. Separation of clinical and pathological stage groups and regrouping of unknown primary tumors are supported by the analysis. The revised staging system provides more accurate prognostication and has been formally accepted by the AJCC staging committee for inclusion in the 8th edition.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Moshiri AS, Nghiem P. Milestones in the staging, classification, and biology of Merkel cell carcinoma. J Natl Compr Cancer Netw. 2014;12:1255–62.

    Google Scholar 

  2. 2.

    Lemos BD, Storer BE, Iyer JG, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63:751–61.

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Iyer JG, Storer BE, Paulson KG, et al. Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. J Am Acad Dermatol. 2014;70:637–43.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Schwartz JL, Griffith KA, Lowe L, et al. Features predicting sentinel lymph node positivity in Merkel cell carcinoma. J Clin Oncol. 2011;29:1036–41.

    Article  PubMed  Google Scholar 

  5. 5.

    Smith FO, Yue B, Marzban SS, et al. Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma. Cancer. 2015;121:3252–60.

    Article  PubMed  Google Scholar 

  6. 6.

    Kachare SD, Wong JH, Vohra NA, Zervos EE, Fitzgerald TL. Sentinel lymph node biopsy is associated with improved survival in Merkel cell carcinoma. Ann Surg Oncol. 2014;21:1624–30.

    Article  PubMed  Google Scholar 

  7. 7.

    Tarantola TI, Vallow LA, Halyard MY, et al. Prognostic factors in Merkel cell carcinoma: analysis of 240 cases. J Am Acad Dermatol. 2013;68:425–32.

    Article  PubMed  Google Scholar 

  8. 8.

    Paulson KG, Iyer JG, Byrd DR, Nghiem P. Pathologic nodal evaluation is increasingly commonly performed for patients with Merkel cell carcinoma. J Am Acad Dermatol. 2013;69:653–4.

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Bichakjian CK, Olencki T, Alam M, et al. Merkel cell carcinoma, version 1.2014. J Natl Compr Cancer Netw. 2014;12:410–24.

    PubMed  Google Scholar 

  10. 10.

    Tarantola TI, Vallow LA, Halyard MY, et al. Unknown primary Merkel cell carcinoma: 23 new cases and a review. J Am Acad Dermatol. 2013;68:433–40.

    Article  PubMed  Google Scholar 

  11. 11.

    Chen KT, Papavasiliou P, Edwards K, et al. A better prognosis for Merkel cell carcinoma of unknown primary origin. Am J Surg. 2013;206:752–7.

    Article  PubMed  Google Scholar 

  12. 12.

    Foote M, Veness M, Zarate D, Poulsen M. Merkel cell carcinoma: the prognostic implications of an occult primary in stage IIIB (nodal) disease. J Am Acad Dermatol. 2012;67:395–9.

    Article  PubMed  Google Scholar 

  13. 13.

    Deneve JL, Messina JL, Marzban SS, et al. Merkel cell carcinoma of unknown primary origin. Ann Surg Oncol. 2012;19:2360–6.

    Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Edge SBBD, Compton CC, et al. AJCC cancer staging manual, 7th edn. New York: Springer; 2010.

    Google Scholar 

  15. 15.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  PubMed  Google Scholar 

  16. 16.

    Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Akhtar S, Oza KK, Wright J. Merkel cell carcinoma: report of 10 cases and review of the literature. J Am Acad Dermatol. 2000;43:755–67.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Fields RC, Busam KJ, Chou JF, et al. Five hundred patients with Merkel cell carcinoma evaluated at a single institution. Ann Surg. 2011;254:465–73; discussion 473–5.

  19. 19.

    Howle JR, Veness MJ. Outcome of patients with microscopic and macroscopic metastatic nodal Merkel cell carcinoma: an Australian experience. Dermatol Surg. 2014;40:46–51.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgment

MAH is supported by NIH T32CA009672-24. The data used in the study are from the NCDB PUF. The ACS-CoC has not verified and are not responsible for the analytic/statistical methodology employed or the conclusions drawn by the investigators.

Disclosures

KLH, MAH, TMJ, CKB, and SLW have no conflict of interest disclosures. PN is a consultant for EMD Serono; travel, accommodations, other expenses from EMD Serono; research funding from Brisol Myers Squibb to PN’s institution. AJS has research funding from MELA Sciences; AJS has stock in Merck, Amgen, Teva, and Pfizer.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Kelly L. Harms MD,PhD.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Harms, K.L., Healy, M.A., Nghiem, P. et al. Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann Surg Oncol 23, 3564–3571 (2016). https://doi.org/10.1245/s10434-016-5266-4

Download citation

Keywords

  • Sentinel Lymph Node Biopsy
  • National Comprehensive Cancer Network
  • Merkel Cell Carcinoma
  • Occult Nodal Metastasis
  • Regional Nodal Basin